Table 1.

Adoptive transfer of Salmonella/CFA-I (H696)-induced CD25⁺CD4⁺ T cells to naïve recipients confers protection against EAE in a TGF-β-dependent fashion.

	Adoptive Transfer/Treatment ^a	Day of Onset ^b	EAE ^c/Total	Max. Score ^d	C.S. ^e
PBS	IgG1	7.4±0.4	15/15	5	57.8
	α-TGF-β	7.8±1.4	15/15	5	46.8
H696	CD25⁺/ IgG1	11.4±0.6 ^{*, †, ++}	9/15	1	2.8 ^{*, †, +}
	CD25⁺/α-TGF-β	7.8±1.8	15/15	5	49.8
	CD25⁻/ IgG1	9±1.2	15/15	4	12.2 ^†
	CD25⁻/α-TGF-β	8.4±0.6	15/15	5	51.2
H647	CD25⁺/ IgG1	8.8±1.3	15/15	5	28 ^{**, ††}
	CD25⁺/α-TGF-β	8.2±0.4	15/15	5	50.6
	CD25⁻/ IgG1	8.4±1.6	15/15	5	39.2
	CD25⁻/α-TGF-β	8.2±0.6	15/15	5	52.2

Two wks after immunization with H696 or H647, cell-sorted CD25⁺CD4⁺ and CD25⁻CD4⁺ T cells were adoptively transferred (5x10⁵) into naïve recipients 1 day prior to EAE induction. EAE was induced as described in Materials and Methods on day 0. Mice were treated with anti-TGF-β mAb or its isotype Ab on the day of adoptive transfer and 4 days post-EAE challenge

Mean day ± SD of clinical disease onset. ^*, p < 0.001 versus PBS/IgG1; ^†, p < 0.001 versus CD25⁺/α-TGF-β; ⁺⁺, p < 0.05 versus CD25⁻/IgG1.

Number of mice with EAE/total number of mice in group.

Maximum (Max.) daily clinical score.

Cumulative disease scores (C.S.) were calculated as the sum of all clinical score from disease onset to the days of sacrifice, divided by the number of mice in each group. ^*, p < 0.001; ^**, p < 0.05 versus PBS/IgG1; ^†, p < 0.001; ^††, p < 0.05 versus CD25⁺/α-TGF-β; ⁺, p < 0.001 versus CD25⁻/IgG1.